MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
+0.030
+0.72%
Closed 16:56 05/05 EDT
OPEN
4.160
PREV CLOSE
4.170
HIGH
4.250
LOW
4.097
VOLUME
33.62K
TURNOVER
--
52 WEEK HIGH
21.28
52 WEEK LOW
4.097
MARKET CAP
39.93M
P/E (TTM)
-1.2880
1D
5D
1M
3M
1Y
5Y
Bellerophon (BLPH) Receives a Buy from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Bellerophon (BLPH), with a price target of $15.00. The company's
SmarterAnalyst · 1d ago
Interstitial Pneumonia Market SWOT Analysis 2021, COVID 19 impact on Top Key Players
May 04, 2021 (The Expresswire) -- The “Interstitial Pneumonia Market” Research Report is framed after handling an in-depth study of the Interstitial...
The Express Wire · 2d ago
At 5.2% CAGR, Nitric Oxide Therapy System Market Size is Expected to Exhibit 36 million USD by 2025
Apr 28, 2021 (Market Insight Reports) -- Selbyville, Delaware Market Study Report LLC adds new research on Nitric Oxide Therapy System market, which is a...
Market Insight Reports · 04/28 17:32
Insider Trends: Bellerophon Therapeutics Insider Receives Stock Award, Trend of Buys Extended
MT Newswires · 04/26 12:49
Interstitial Lung Disease (ILD) Market Report 2021 Growth Factors, Research Methodology With Impact of COVID-19 and Global Forecast 2026
The Express Wire · 04/26 10:54
Clinical Trials Market to Witness US$ 69.7 Billion Revenue by 2030
Apr 22, 2021 (Market Stats News via COMTEX) -- The global Clinical Trials marketsize is expected to be worth around US$ 69.7 billion by 2030 from US$ 44.3...
Market Stats News · 04/22 11:21
Inhaled Nitric Oxide (NO) Delivery Systems Market Size, Share, Industry Analysis and Regional Forecast 2020-2027
Apr 22, 2021 (The Expresswire) -- The rising prevalence of pulmonary hypertension is expected to spur opportunities for the market, states Fortune Business...
The Express Wire · 04/22 06:32
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/16 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLPH. Analyze the recent business situations of Bellerophon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLPH stock price target is 21.33 with a high estimate of 30.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 6.98M
% Owned: 73.44%
Shares Outstanding: 9.51M
TypeInstitutionsShares
Increased
12
209.64K
New
1
10.08K
Decreased
12
99.83K
Sold Out
4
49.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Director
Jonathan Peacock
Chief Executive Officer/Chief Financial Officer/Director
Fabian Tenenbaum
Chief Financial Officer/Secretary
Assaf Korner
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Vice President - Administration
Amy Edmonds
Other
Wassim Fares
Other
Peter Fernandes
Director
Ted Wang
Independent Director
Naseem Amin
Independent Director
Matthew Bennett
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Andre Moura
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
No Data
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.